- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00750867
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease.
Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity.
This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female older than 17 years.
- Clinical diagnosis of probable multiple system atrophy
- Provide written informed consent to participate in the study
- Understand that they may withdraw their consent at any time
Exclusion Criteria:
- Women who are pregnant or lactating
- In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness.
- In the investigator's opinion, the subjects are significantly dehydrated, as determined by clinical evaluation including measurement of skin turgor, blood urea nitrogen and creatinine values.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Interventions included monthly infusions of intravenous immunoglobulin.
|
The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events up to Six Months Post-treatment
Time Frame: Monthly, up to 8 months (including the screening visit and the final visit)
|
The primary outcome measure was to evaluate the safety and tolerability of the IVIG infusions in patients with multiple system atrophy.
The primary endpoint was defined as the frequency of adverse events (AE).
AEs including their severity and relationship to the IVIG were assessed throughout the study and at least 60 days after the last infusion.
The AEs were considered to be related to the IVIG infusion (infusional AE) if they occurred during an infusion or within 72 hours afterwards.
Non-infusional AEs were further classified as possible related to IVIG or likely not related to IVIG.
Serious AEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization.
Any AE was defined as occurrence of any symptom regardless of intensity grade.
|
Monthly, up to 8 months (including the screening visit and the final visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary Efficacy of IVIg for Treatment of MSA.
Time Frame: Monthly, up to 8 months (including the screening visit and the final visit)
|
The secondary outcome measure was to evaluate the preliminary efficacy of IVIG for the treatment of MSA.
The primary efficacy endpoint was change of the Unified MSA Rating Scale (UMSARS-I and UMSAR-II) compared to baseline.
UMSARS-I and UMSARS-II are validated semiquantitative rating scales for evaluation of severity of MSA.
UMSARS-I comprises a historical review of disease-related impairments and UMSARS-II comprises motor examination.
UMSARS-I has 12 questions, each with assigned score 0-4, where 0 is normal and > are abnormal responses.
Total range of UMSARS-I is 0 to 48.
UMSARS-II has 12 items rated by an examiner, each with assigned score 0-4, where 0 is normal and > are abnormal responses.
Total range of UMSARS-II is 0 to 56.
The scores of UMSARS-I and UMSARS-II at baseline (month 1) was compared with the scores obtained at the final visit (month 8) which was 8 months apart.
The interventions occured at months 2-7, total six times.
|
Monthly, up to 8 months (including the screening visit and the final visit)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Peter Novak, MD, PhD, University of Massachusetts, Worcester
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Pathological Conditions, Anatomical
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Hypotension
- Atrophy
- Multiple System Atrophy
- Shy-Drager Syndrome
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- H-12784
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple System Atrophy
-
Brigham and Women's HospitalBiohaven Pharmaceuticals, Inc.CompletedMultiple System Atrophy | Multiple System Atrophy, Parkinson Variant (Disorder) | Multiple System Atrophy, Cerebellar Variant | Multiple System Atrophy (MSA) With Orthostatic HypotensionUnited States
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMultiple System Atrophy - Parkinsonian Subtype (MSA-P) | Multiple System Atrophy - Cerebellar Subtype (MSA-C)United States
-
Dana HorakovaUnknownMultiple Sclerosis | Cognitive Change | Atrophy Brain | Atrophy; Spinal CordCzechia
-
Ono Pharmaceutical Co. LtdRecruitingMultiple System Atrophy (MSA)United States
-
Biohaven Pharmaceuticals, Inc.No longer availableMultiple System Atrophy (MSA)United States
-
University Hospital, BordeauxCompleted
-
AstraZenecaCompletedMultiple System Atrophy, MSAUnited States, Finland, Austria, France, Sweden, United Kingdom, Italy
-
Cytora Ltd.RecruitingMultiple System Atrophy | MSA - Multiple System AtrophyIsrael
-
Samsung Medical CenterUnknownMultiple System Atrophy, Cerebellar Variant (Disorder)Korea, Republic of
-
University of Texas Southwestern Medical CenterRecruiting
Clinical Trials on intravenous immunoglobulin (IVIg)
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde... and other collaboratorsCompleted
-
Johns Hopkins UniversityTerminatedAutoimmunity | Dysmotility SyndromeUnited States
-
University of PittsburghBayer; Shadyside Hospital FoundationTerminatedClostridium Difficile-associated Diarrhea (CDAD)United States
-
Kanecia Obie ZimmermanEnrolling by invitationLong COVID | Long Covid-19 | Long Coronavirus Disease 2019 (Covid19)United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Minnesota; International Network for Strategic Initiatives in...CompletedInfluenza A | Influenza BUnited States, Australia, Denmark, United Kingdom
-
University of MinnesotaCSL Behring; BriovaRx Infusion ServicesCompletedChronic Inflammatory Demyelinating PolyneuropathyUnited States
-
National Institute of Neurological Disorders and...CompletedDemyelinating Diseases | ParaproteinemiasUnited States
-
University of Texas Southwestern Medical CenterGrifols Biologicals, LLC; Dysautonomia InternationalCompletedPostural Tachycardia SyndromeUnited States
-
Assiut UniversityCompleted